Emergent BioSolutions (NYSE:EBS) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a report released on Tuesday.

EBS has been the topic of several other reports. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Down 9.3 %

Shares of EBS traded down $0.86 during mid-day trading on Tuesday, hitting $8.41. 1,084,257 shares of the company traded hands, compared to its average volume of 3,365,321. The business has a 50 day moving average of $8.63 and a 200 day moving average of $7.96. The company has a market capitalization of $455.65 million, a PE ratio of -2.11 and a beta of 1.57. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10.

Hedge Funds Weigh In On Emergent BioSolutions

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after buying an additional 436,911 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Emergent BioSolutions by 5.8% in the second quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 52,144 shares in the last quarter. American Century Companies Inc. boosted its position in Emergent BioSolutions by 240.9% during the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after acquiring an additional 623,201 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after acquiring an additional 316,700 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in Emergent BioSolutions by 75.4% in the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after acquiring an additional 233,341 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.